Kamada Ltd.
KMDAKamada Ltd. is a global biopharmaceutical company specializing in the research, manufacturing, and commercialization of specialty pharmaceuticals derived from human plasma. The company’s portfolio includes 6 FDA-approved plasma-derived products, which are distributed in over 30 international markets.
Drugs in Pipeline
11
Phase 3 Programs
5
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
5wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How KMDA's past catalysts played out
Active rabies vaccine (US-FDA approved)
Rabies
KamRAB - HRIG
Rabies
Alpha 1-Antitrypsin
Alpha 1-Antitrypsin Deficiency
Kamada AAT for inhalation
Emphysema
Kamada-API
Alpha 1-Antitrypsin Deficiency
Alpha-1 Antitrypsin 40mg (AAT, Glassia®)
Type 1 Diabetes Mellitus
Aerosolized, human, plasma-derived Alpha-1 Antitrypsin
Cystic Fibrosis
GLASSIA® and Institution standard of care (SOC)
Transplantation, Lung Rejection
Alpha-1 Antitrypsin
New Onset Type-1 Diabetes
Kamada-AAT for Inhalation, 80mg
Alpha-1 Antitrypsin Deficiency
Kamada Anti-SARS-CoV-2
Covid19
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Active rabies vaccine (US-FDA approved) | Phase 3 | Rabies | - | - |
KamRAB - HRIG | Phase 3 | Rabies | - | - |
Alpha 1-Antitrypsin | Phase 3 | Alpha 1-Antitrypsin Deficiency | - | - |
Kamada AAT for inhalation | Phase 3 | Emphysema | - | - |
Kamada-API | Phase 3 | Alpha 1-Antitrypsin Deficiency | - | - |
Alpha-1 Antitrypsin 40mg (AAT, Glassia®) | Phase 2 | Type 1 Diabetes Mellitus | - | - |
Aerosolized, human, plasma-derived Alpha-1 Antitrypsin | Phase 2 | Cystic Fibrosis | - | - |
GLASSIA® and Institution standard of care (SOC) | Phase 2 | Transplantation, Lung Rejection | - | - |
Alpha-1 Antitrypsin | Phase 2 | New Onset Type-1 Diabetes | - | - |
Kamada-AAT for Inhalation, 80mg | Phase 2 | Alpha-1 Antitrypsin Deficiency | - | - |
Kamada Anti-SARS-CoV-2 | Phase 2 | Covid19 | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Kamada Ltd.'s drug pipeline?→
CatalystAlert tracks 11 drug candidates in Kamada Ltd.'s (KMDA) pipeline across Phase 3, Phase 2. Its lead program is Active rabies vaccine (US-FDA approved) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kamada Ltd.'s next FDA catalyst?→
Kamada Ltd.'s (KMDA) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KMDA biotech catalysts?→
Add KMDA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kamada Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.